Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

ADCT

Adc Therapeutics SA

Dec 13 • 04:00PM ET

1.89

Dollar change -0.09
Percentage change -4.55	%

Healthcare • Biotechnology • Switzerland • NYSE

Peers: GILD PFE AMGN LLY REGN VRTX JAZZ MRNA BMY INCY

| Held by: IWM VTWO IWO IWN IWC VTWG IWV RSSL GSSC VTWV

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.40	Insider Own	19.50%	Shs Outstand	96.69M	Perf Week	-39.62%
Market Cap	182.75M	Forward P/E	-	EPS next Y	-1.52	Insider Trans	4.10%	Shs Float	77.83M	Perf Month	-32.98%
Income	-212.15M	PEG	-	EPS next Q	-0.42	Inst Own	68.81%	Short Float	3.87%	Perf Quarter	-38.64%
Sales	70.72M	P/S	2.58	EPS this Y	41.93%	Inst Trans	9.98%	Short Ratio	4.29	Perf Half Y	-42.73%
Book/sh	-1.78	P/B	-	EPS next Y	10.79%	ROA	-52.00%	Short Interest	3.01M	Perf Year	12.50%
Cash/sh	2.84	P/C	0.67	EPS next 5Y	-	ROE	-705.53%	52W Range	1.01 - 6.04	Perf YTD	13.86%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-10.46%	ROI	-	52W High	-68.71%	Beta	1.54
Dividend TTM	-	Quick Ratio	4.68	Sales past 5Y	91.46%	Gross Margin	91.81%	52W Low	87.13%	ATR (14)	0.37
Dividend Ex-Date	-	Current Ratio	4.92	EPS Y/Y TTM	-9.33%	Oper. Margin	-193.15%	RSI (14)	40.93	Volatility	25.64% 16.29%
Employees	162	Debt/Eq	-	Sales Y/Y TTM	-42.30%	Profit Margin	-300.00%	Recom	1.29	Target Price	8.40
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	27.82%	Payout	-	Rel Volume	2.09	Prev Close	1.98
Sales Surprise	0.17%	EPS Surprise	-6.33%	Sales Q/Q	27.40%	Earnings	Nov 07 BMO	Avg Volume	702.05K	Price	1.89
SMA20	-17.32%	SMA50	-30.56%	SMA200	-44.96%	Trades		Volume	1,469,580	Change	-4.55%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-08-24	Initiated	Stephens	Overweight	$6
May-30-24	Initiated	Cantor Fitzgerald	Overweight
Mar-28-24	Initiated	Guggenheim	Buy	$11
Aug-10-23	Upgrade	JP Morgan	Underweight → Neutral
Apr-24-23	Downgrade	BofA Securities	Neutral → Underperform	$7 → $2
Dec-06-22	Initiated	CapitalOne	Overweight	$12
Nov-09-22	Downgrade	BofA Securities	Buy → Neutral	$14 → $7
Sep-21-22	Initiated	JP Morgan	Overweight	$5
Sep-09-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$17 → $11
Nov-09-21	Initiated	Wolfe Research	Outperform	$44
Aug-17-21	Resumed	Jefferies	Buy	$40
Aug-09-21	Initiated	RBC Capital Mkts	Outperform	$33
Jun-15-21	Initiated	Cantor Fitzgerald	Overweight	$13
Dec-03-20	Initiated	Stifel	Hold	$42
Oct-29-20	Initiated	H.C. Wainwright	Buy	$47
Jun-09-20	Initiated	Cowen	Outperform
Jun-09-20	Initiated	BofA/Merrill	Buy	$45

Show Previous Ratings

Dec-11-24 07:30AM	ADC Therapeutics Announces Positive Initial Data from LOTIS-7 Clinical Trial Evaluating ZYNLONTA in Combination with Bispecific Antibody in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (PR Newswire) -36.21%
Dec-09-24 07:30AM	ADC Therapeutics Announces The Lancet Haematology Publication of Data from Investigator-Initiated Trial Evaluating ZYNLONTA in Combination with Rituximab to Treat Relapsed/Refractory Follicular Lymphoma (PR Newswire)
Dec-06-24 07:30AM	ADC Therapeutics to Provide Initial Data Update on LOTIS-7 Clinical Trial (PR Newswire) +63.02%
Dec-02-24 04:30PM	ADC Therapeutics Makes Grants to New Employees Under Inducement Plan (PR Newswire) -10.78%
Nov-14-24 02:02AM	BerGenBio ASA (FRA:7BG0) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst Leadership ... (GuruFocus.com) -6.03%
01:14PM	Loading…
Nov-08-24 01:14PM	ADC Therapeutics Faces Competitive Oncology Market But Analyst Sees 100% Upside - Here's Why (Benzinga)
Nov-07-24 08:50AM	ADC Therapeutics SA (ADCT) Reports Q3 Loss, Lags Revenue Estimates (Zacks) -8.44%
07:30AM	ADC Therapeutics Reports Third Quarter and Year-to-Date 2024 Financial Results and Provides Operational Update (PR Newswire)
Nov-06-24 07:41AM	What To Expect From ADC Therapeutics SA (ADCT) Q3 2024 Earnings (GuruFocus.com)
Nov-05-24 09:47AM	ADC Therapeutics Announces Investigator-Initiated Study Abstracts Accepted for Presentation at the 66th ASH Annual Meeting (PR Newswire)
Nov-04-24 07:15AM	ADC Therapeutics to Present at November Investor Conferences (PR Newswire)
Nov-01-24 04:05PM	ADC Therapeutics Makes Grants to New Employees Under Inducement Plan (PR Newswire)
09:40AM	Is ADC Therapeutics (ADCT) Stock Outpacing Its Medical Peers This Year? (Zacks)
Oct-31-24 07:15AM	ADC Therapeutics to Host Third Quarter 2024 Financial Results Conference Call on November 7, 2024 (PR Newswire)
Oct-01-24 04:05PM	ADC Therapeutics Makes Grants to New Employees Under Inducement Plan (GlobeNewswire)
04:05PM	Loading…
Sep-03-24 04:05PM	ADC Therapeutics Makes Grants to New Employees Under Inducement Plan (GlobeNewswire) -5.86%
07:15AM	ADC Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Aug-06-24 08:40AM	ADC Therapeutics SA (ADCT) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
07:30AM	ADC Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational Update (GlobeNewswire)
Aug-01-24 04:05PM	ADC Therapeutics Makes Grants to New Employees Under Inducement Plan (GlobeNewswire) -7.83% -5.88%
Jul-30-24 07:15AM	ADC Therapeutics to Host Second Quarter 2024 Financial Results Conference Call on August 6, 2024 (GlobeNewswire)
Jul-11-24 03:24PM	7 Growth Stocks to Buy for Under $5 for Massive Gains (InvestorPlace) +20.32%
Jul-08-24 02:00AM	Myricx Bio Announces 90m ($114m) Series A Financing to Advance its Novel NMTi-ADC Therapeutics into Clinical Development (GlobeNewswire) -6.13%
Jul-01-24 04:05PM	ADC Therapeutics Makes Grants to New Employees Under Inducement Plan (GlobeNewswire) +16.46% -5.43%
Jun-27-24 07:15AM	ADC Therapeutics Set to Join Russell 2000 and Russell 3000 Indexes (GlobeNewswire)
Jun-13-24 02:31PM	Stocks to Buy: 3 Biotech Bargains Delivering Breakthroughs on a Budget (InvestorPlace)
Jun-03-24 04:05PM	ADC Therapeutics Makes Grants to New Employees Under Inducement Plan (GlobeNewswire) +5.74%
May-30-24 07:15AM	ADC Therapeutics to Participate in the Jefferies Global Healthcare Conference (GlobeNewswire)
May-15-24 07:15AM	ADC Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ (GlobeNewswire)
May-09-24 07:01PM	Insider Sale: CEO Ameet Mallik Sells 29,731 Shares of ADC Therapeutics SA (ADCT) (GuruFocus.com) -5.91%
07:15AM	Loading…
07:15AM	ADC Therapeutics to Participate in 2024 RBC Capital Markets Global Healthcare Conference (GlobeNewswire)
May-07-24 08:55AM	ADC Therapeutics SA (NYSE:ADCT) Q1 2024 Earnings Call Transcript (Insider Monkey) +8.54%
08:44AM	HC Wainwright Adjusts Price Target on ADC Therapeutics to $8 From $9, Maintains Buy Rating (MT Newswires)
May-06-24 10:53AM	ADCT Stock Earnings: ADC Therapeutics Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace) -9.18%
08:22AM	ADC Therapeutics Launches $105 Million Offering; Shares Up 2% Pre-Bell (MT Newswires)
07:30AM	ADC Therapeutics Announces $105 Million Underwritten Offering of Common Shares and Pre-Funded Warrants (GlobeNewswire)
07:20AM	ADC Therapeutics SA (ADCT) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
06:55AM	ADC Therapeutics SA's Cancer Drug Candidate Shows High Response Rate in Phase 2 Trial (MT Newswires)
06:10AM	ADC Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
06:00AM	ADC Therapeutics Announces Initial Data from Investigator-Initiated Phase 2 Clinical Trial of ZYNLONTA in Patients with Relapsed/Refractory Marginal Zone Lymphoma (GlobeNewswire)
May-01-24 04:05PM	ADC Therapeutics Makes Grants to New Employees Under Inducement Plan (GlobeNewswire) +6.80%
07:00AM	ADC Therapeutics to Host First Quarter 2024 Financial Results and Pipeline Update Conference Call on May 6, 2024 (GlobeNewswire)
Apr-16-24 08:30AM	ADC Therapeutics Accelerates R&D with Genedata Biologics (PR Newswire)
Apr-04-24 07:00AM	ADC Therapeutics Announces Updates on LOTIS-7 Clinical Trial Evaluating ZYNLONTA in Combination with Glofitamab or Mosunetuzumab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma (GlobeNewswire) +6.32%
Apr-03-24 07:00AM	ADC Therapeutics to Host a Virtual Research Investor Event on Tuesday, April 9, 2024 (GlobeNewswire)
Apr-01-24 04:05PM	ADC Therapeutics Makes Grants to New Employees Under Inducement Plan (GlobeNewswire)
Mar-15-24 12:30PM	ADC Therapeutics SA (NYSE:ADCT) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-14-24 05:16AM	Q4 2023 ADC Therapeutics SA Earnings Call (Thomson Reuters StreetEvents)
Mar-13-24 08:51AM	ADC Therapeutics SA (ADCT) Reports Mixed 2023 Financial Results Amid Strategic Reset (GuruFocus.com) -12.36%
08:20AM	ADC Therapeutics SA (ADCT) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:00AM	ADC Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates (GlobeNewswire)
Mar-06-24 07:15AM	ADC Therapeutics to Participate in the Guggenheim 5th Annual Healthy Altitudes Summit (GlobeNewswire)
07:00AM	ADC Therapeutics to Host Fourth Quarter and Year-End 2023 Financial Results Conference Call on March 13, 2024 (GlobeNewswire)
Mar-05-24 05:45PM	ADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire)
Feb-27-24 07:00AM	ADC Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference (GlobeNewswire)
Feb-20-24 10:00AM	Earnings Preview: ADC Therapeutics SA (ADCT) Q4 Earnings Expected to Decline (Zacks) -8.88%
Feb-16-24 03:57AM	15 Top Performing European Stocks So Far in 2024 (Insider Monkey) +6.44%
Feb-15-24 11:57AM	The 3 Biotech Stocks That Could Make Your February Unforgettable (InvestorPlace)
Feb-08-24 01:15PM	The 3 Most Undervalued Biotech Stocks to Buy in February 2024 (InvestorPlace)
Jan-19-24 01:05PM	ADC Therapeutics (ADCT) Rises 43% in a Month: Here's Why (Zacks)
09:40AM	Is ADC Therapeutics (ADCT) Outperforming Other Medical Stocks This Year? (Zacks)
Jan-04-24 10:05AM	ADC Therapeutics, Aldeyra start off New Year with program discontinuations (FierceBiotech.com) +13.25%
07:15AM	ADC Therapeutics Regains Compliance with NYSE Continued Listing Standards (GlobeNewswire)
07:00AM	ADC Therapeutics Provides Business Updates (GlobeNewswire)
Dec-12-23 05:15AM	ADC Therapeutics Announces Initial Results from Investigator-Initiated Phase 2 Clinical Trial Evaluating ZYNLONTA in Combination with Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma (FL) (GlobeNewswire)
Nov-20-23 02:40AM	Sobi to present new data at ASH 2023 Annual Meeting (PR Newswire)
Nov-15-23 03:00AM	Myricx Bio Appoints Dr Chris Martin, Biotech Entrepreneur and ADC Pioneer, as Chairman of its Board of Directors (GlobeNewswire) +6.15%
Nov-08-23 01:26PM	ADC Therapeutics SA (NYSE:ADCT) Q3 2023 Earnings Call Transcript (Insider Monkey) -17.26%
01:03AM	Q3 2023 ADC Therapeutics SA Earnings Call (Thomson Reuters StreetEvents)
Nov-07-23 08:15AM	ADC Therapeutics SA (ADCT) Reports Q3 Loss, Lags Revenue Estimates (Zacks) -15.97%
07:15AM	ADC Therapeutics Receives NYSE Notice of Non-Compliance With Continued Listing Standards (GlobeNewswire)
07:00AM	ADC Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire)
Nov-06-23 07:00AM	ADC Therapeutics to Participate in the Jefferies London Healthcare Conference (GlobeNewswire) +7.87%
Nov-02-23 05:50PM	Puma Biotech (PBYI) Tops Q3 Earnings Estimates (Zacks) +14.27%
10:10AM	ADC Therapeutics Announces Abstracts Accepted for Presentation at the 65th ASH Annual Meeting (GlobeNewswire)
Nov-01-23 10:01AM	Ligand Pharmaceuticals (LGND) Earnings Expected to Grow: Should You Buy? (Zacks)
Oct-31-23 10:01AM	ADC Therapeutics SA (ADCT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Oct-24-23 07:00AM	ADC Therapeutics to Host Third Quarter 2023 Financial Results Conference Call on November 7, 2023 (GlobeNewswire)
Oct-04-23 04:00AM	Myricx Expands its ADC Expertise with the Appointment of Francesca Zammarchi as CSO (GlobeNewswire)
Sep-05-23 07:00AM	ADC Therapeutics to Participate in September Investor Conferences (GlobeNewswire) -7.38%
Aug-30-23 07:33PM	ADC Therapeutics Announces Updates on ZYNLONTA® LOTIS Clinical Trial Programs at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) (GlobeNewswire)
Aug-14-23 10:51AM	Atreca (BCEL) Suspends Lead Drug Evaluation, Stock Falls 37% (Zacks)
Aug-11-23 10:53AM	Catalyst (CPRX) Q2 Earnings & Sales Top, 2023 Outlook Raised (Zacks)
Aug-10-23 10:31AM	Novo Nordisk (NVO) Q2 Earnings and Sales Miss, 2023 View Up (Zacks) +7.33%
Aug-09-23 12:09PM	Horizon (HZNP) Q2 Earnings Top, Krystexxa & Uplizna Boost Sales (Zacks) -6.25%
Aug-08-23 11:01PM	Q2 2023 ADC Therapeutics SA Earnings Call (Thomson Reuters StreetEvents) +11.89%
10:48AM	Zoetis' (ZTS) Q2 Earnings and Revenues Surpass Estimates (Zacks)
08:15AM	ADC Therapeutics SA (ADCT) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
07:00AM	ADC Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire)
Aug-07-23 05:25PM	MannKind (MNKD) Reports Break-Even Earnings for Q2 (Zacks)
Aug-04-23 08:40AM	Intra-Cellular (ITCI) Q2 Earnings & Sales Top, '23 View Raised (Zacks)
08:12AM	Ultragenyx (RARE) Q2 Loss Wider Than Expected, Revenues Beat (Zacks)
Aug-03-23 11:48AM	Corcept (CORT) Beats on Q2 Earnings, Ups '23 Sales View (Zacks)
11:45AM	Editas' (EDIT) Q2 Earnings Beat, Sales Miss, Pipeline in Focus (Zacks)
08:02AM	Acadia (ACAD) Q2 Earnings & Revenues Beat Estimates, '23 View Up (Zacks)
Aug-02-23 12:45PM	Pacira (PCRX) Q2 Earnings and Sales Miss, '23 View Updated (Zacks)
12:42PM	Blueprint (BPMC) Q2 Earnings and Revenues Beat Estimates (Zacks)
Aug-01-23 10:45AM	Apellis (APLS) Q2 Earnings Top, Syfovre Sales Boost Revenues (Zacks)
07:22AM	Are Investors Undervaluing ADC Therapeutics SA (NYSE:ADCT) By 27%? (Simply Wall St.)
07:00AM	ADC Therapeutics to Host Second Quarter 2023 Financial Results Conference Call on August 8, 2023 (GlobeNewswire)

ADC Therapeutics SA is a clinical-stage biotechnology company. It engages in the research and development and commercialization of targeted antibody drug conjugates for patients with hematological malignancies and solid tumors. Its clinical-stage product candidates include loncastuximab tesirine, camidanlumab tesirine, and ADCT-602. The company was founded by Christopher Martin on June 6, 2011 and is headquartered in Epalinges, Switzerland.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Redmile Group, LLC	10% Owner	Dec 04 '24	Sale	2.07	25,352	52,479	15,566,731	Dec 06 09:00 PM
Redmile Group, LLC	10% Owner	Jul 01 '24	Buy	2.81	400,000	1,124,000	15,669,217	Jul 03 08:00 PM
Redmile Group, LLC	10% Owner	Jul 01 '24	Buy	2.81	400,000	1,124,000	12,995,040	Jul 03 08:00 PM
Azelby Robert	Director	Jun 17 '24	Sale	2.89	6,995	20,216	53,005	Jun 18 09:45 PM
BIZZARI JEAN-PIERRE	Director	Jun 17 '24	Sale	2.89	6,995	20,216	79,502	Jun 18 09:43 PM
Hug Peter	Director	Jun 17 '24	Sale	2.89	1,193	3,448	182,644	Jun 18 09:41 PM
Monges Viviane	Director	Jun 17 '24	Sale	2.89	1,437	4,153	106,627	Jun 18 09:40 PM
Pfisterer Thomas	Director	Jun 17 '24	Sale	2.89	1,437	4,153	213,900	Jun 18 09:38 PM
Sandor Victor	Director	Jun 17 '24	Sale	2.89	6,995	20,216	80,886	Jun 18 09:37 PM
Squarer Ron	Director	Jun 17 '24	Sale	2.89	6,995	20,216	80,663	Jun 18 09:35 PM
MALLIK AMEET	Chief Executive Officer	May 07 '24	Sale	4.48	29,731	133,195	1,167,348	May 09 04:06 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ADCT

Adc Therapeutics SA

Upgrade your FINVIZ experience